AstraZeneca, an international biopharmaceutical company, launched a new high-tech manufacturing process at its plant in Vorsino industrial park of Kaluga region. One of the first medicines to be produced on a new line will be osimertinib, an innovative targeted agent for the treatment of lung cancer.
The opening of the new production line will allow to manufacture not only osimertinib, but also one drug for the treatment of cardiovascular diseases, one drug for the treatment of type 2 diabetes, and another oncological drug for the treatment of lung cancer. The total output will be up to 3.5 million packages of innovative AstraZeneca medicines a year. According to the current schedule of localization, the manufacturing is expected to reach full cycle in 2020.
AstraZeneca plant produces more than 30 innovative drugs for the treatment of diseases in such therapeutic areas as oncology, cardiology, gastroenterology, psychiatry, and pulmonology. This represents almost 80% of the company’s portfolio in Russia.
Gennady Pyatsky, the General Director of AstraZeneca Industries LLC, said, “Among 30 plants of AstraZeneca, only 3 will manufacture the new drug, including the enterprise in Kaluga. After the commissioning of new production lines, the capacity of the plant will reach 40 million packages a year.”